Sangamo Therapeutics Inc. has signed an evaluation and option agreement with Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly & Co., through which Prevail has been granted rights to evaluate certain proprietary adeno-associated virus (AAV) capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets.